Ibuprofen 400 mg for PSA

Phase-Based Progress Estimates
University of Chicago, Chicago, IL
PSA+1 More
Ibuprofen 400 mg - Drug
What conditions do you have?

Study Summary

This trial will test whether ibuprofen can lower PSA levels in men with slightly elevated levels, which may help prevent prostate cancer. The trial will use Ibuprofen 400 mg to treat PSA, as it has been approved by the FDA for a different condition. There will be no placebo group in this trial. Patients will be able to do the treatment online.

Eligible Conditions

  • PSA
  • Elevated Serum PSA

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Baseline, 6 weeks

Baseline, 6 weeks
Change of International Prostate Symptom Score (IPSS) compared with baseline
Change of serum PSA compared with baseline

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Active Control
Experimental Treatment

200 Total Participants · 2 Treatment Groups

Primary Treatment: Ibuprofen 400 mg · No Placebo Group · Phase 4

Experimental Group · 1 Intervention: Ibuprofen 400 mg · Intervention Types: Drug
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:
First Studied
Drug Approval Stage
How many patients have taken this drug
Ibuprofen 400 mg
Completed Phase 4

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 6 weeks
Closest Location: University of Chicago · Chicago, IL
Photo of University of Chicago 1Photo of University of Chicago 2Photo of University of Chicago 3
2004First Recorded Clinical Trial
1 TrialsResearching PSA
712 CompletedClinical Trials

Who is running the clinical trial?

University of ChicagoLead Sponsor
909 Previous Clinical Trials
726,747 Total Patients Enrolled
1 Trials studying PSA
1,500 Patients Enrolled for PSA
Scott Eggener, MDPrincipal InvestigatorUniversity of Chicago
3 Previous Clinical Trials
262 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Male Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have no clinical symptoms concerning acute urinary tract infection.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.